Computed Tomography (CT) Perfusion Imaging of Lung Cancer

Carcinoma, Non Small Cell Lung Clinical Trial

Official title: CTP (Computed Tomography Perfusion) Imaging of Lung Cancer

Status Terminated

Clinical Trial Summary

This is an experimental study of the feasibility and efficacy of CT perfusion (CTP) imaging (CT blood flow measurements) in subjects with non-small cell lung cancer.

Clinical Trial Description

Drug/Device Information

1) Contrast

30 cc bolus of a low osmolar, iodinated CT contrast agent, which is FDA approved and used in the clinical CT Imaging procedure.

2) Scanner

The 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI) is FDA approved for clinical CT imaging

Research Design and Methods

1) Primary Endpoint

1. Diagnostic yield of tumor perfusion measurements using a contrast assisted computed tomography technique.

2) Secondary Endpoints

1. Reproducibility of tumor blood flow estimates derived by CT.

2. Assessment of the association between tumor vascularity responses after two cycles of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria (RECIST).

3. Predictive value of tumor blood flow for patient survival, compared to the predictive power of tumor size determinations. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Carcinoma, Non Small Cell Lung
• Carcinoma, Non-Small-Cell Lung

• NCT number: NCT00905801
• Study type: Interventional
• Source: University of Pittsburgh
• Status: Terminated
• Phase: N/A
• Start date: June 2009
• Completion date: September 2014